NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE264457 Query DataSets for GSE264457
Status Public on May 17, 2024
Title Disrupting TSLP - TSLP receptor interactions via small molecule inhibitors yields a novel and efficient treatment option for atopic diseases
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Thymic stromal lymphopoietin (TSLP) is a key player in the pathogenesis of atopic diseases. Its pathophysiological relevance has sparked great interest in therapeutically targeting TSLP. Yet, so far, no small-mo lecule TSLP inhibitors exist due to the challenging nature of disrupting the protein-protein interaction between TSLP and its receptor. Here, we report the development of small-molecule TSLP receptor inhibitors using structure- based virtual screening and docking of >1,000,000 compounds followed by iterative chemical synthesis. BP79 emerged as our lead compound that effectively abrogates TSLP-triggered cytokine release at low micromolar concentrations. Topical application of BP79 yields efficient skin absorption followed by significant downregulation of atopy-relevant proinflammatory cytokines in immunocompetent skin disease models. For further analysis, we developed a human atopic disease drug discovery platform using microfluidic multi-organ chips. Here, topical application of BP79 onto atopic-like skin disease models that were co -cultivated with lung models in the presence of Th2 cells effectively suppressed immune cell infiltration and key atopy mediators including IL-13, IL-4, TSLP, and periostin, while upregulating skin barrier prote ins such as filaggrin. RNA-Seq analysis corroborated these findings and also indicated protective downstream effects on the lung epithelium. To the best of our knowledge, this represents the first report of a po tent and safe small molecule TSLPR inhibitor which has the potential to expand the therapeutic and preventive options in atopic diseases. Further, it serves as a starting point for further developments in target ing TSLP as a central player of inflammation.
 
Overall design Two tissues (skin and lung) were divided between two 3D model conditions ("atopic-like" and normal) and then treated with BP79 compound or left untreated. Differential gene expression was used to infer regulated genes in either condition, and gene set enrichment analysis was used for discerning of relevant biological pathways
 
Contributor(s) Protim Adhikary P, Weiner J, Beule D, Hedtrich S
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Apr 19, 2024
Last update date May 17, 2024
Contact name January 3rd Weiner
E-mail(s) january.weiner@gmail.com
Phone 030450543049
Organization name Berlin Institute of Health, Charité Medical University of Berlin
Department CUBI
Street address Charitéplatz 1
City Berlin
ZIP/Postal code 10117
Country Germany
 
Platforms (1)
GPL30173 NextSeq 2000 (Homo sapiens)
Samples (18)
GSM8218514 Brionchial epithelial tissue, normal-like model, untreated, replicate 20220412-R_S52
GSM8218515 Skin tissue, normal-like model, untreated, replicate R_S51
GSM8218516 Brionchial epithelial tissue, atopic-like model, treated with BP79, replicate 1_S3
Relations
BioProject PRJNA1102434

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE264457_raw_counts.tsv.gz 1.1 Mb (ftp)(http) TSV
SRA Run SelectorHelp
Raw data are available in SRA

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap